Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/63960
Type
Papers presented at eventsCopyright
Restricted access
Collections
Metadata
Show full item record
IS THE CLEC5A INVOLVED IN IMMUNE RESPONSE CONTROL AFTER A MRNA COVID-19 BIVALENT VACCINE USING A MICE MODEL?
Author
Affilliation
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia.em imunobiológicos (Bio-manguinhos). Rio de Janeiro, RJ, Brasil.
Abstract
Introduction: Several vaccines platforms have been used to improve the vaccine development for
coronavirus- 2019 (COVID-19), including viral vectors and mRNA vaccines with satisfactory safety and
efficacy data, and they were licensed since 2021 worldwide, including Brazil. Although the development
of new vaccines was possible and able to reduce severe disease and deaths caused by coronavirus, variants
of concern emerged, as Omicron strain, showing to be more transmissible as well as a strategy for viral
escape from immunization.
Objectives: Regarding that, this study aimed to verify the role of the CLEC5A gene expression, such as
the inflammatory genes during a mRNA vaccination using a commercial bivalent vaccine previously and
after vaccination.
Methodology: Gene expression of CLEC5A, IL1B, IL6, IL12, NFKB, TNFA, IFNA, IFNB, and IFNG, were
used to measure the levels of RNAm expressed by cells from immunized mice with a bivalent commercial
vaccine (BNT162b2 BA.4/5 bivalent mRNA vaccine (Pfizer–BioNtech) before and after viral challenge
(SARS-CoV-2 Gama variant). For this, we used a mice model to analyze the role of this pathway in the
attempt of the disease control by immunization.
Results: The results showed that CLEC5A is activated after viral challenge (0.91-fold-change), but it was
reduced post immunization (0.37-fold-change). Taken together IFNA was highly expressed by immunized
mice and diminished significantly after viral challenge (p<0.01), showing a possible regulation of this
pathway by the virus. In addition, IFNG was activated by immunization using a commercial bivalent
vaccine and did not change after viral challenge. The inflammatory genes, as TNFA and IL12 presented an
increase after viral challenged in vaccinated group compared with immunized mice not challenged with
the virus, but it was not significant.
Conclusion: Our preclinical findings showed that CLEC5A can be part of a panel to evaluate COVID-19
immunization, as well as can monitor the inflammation and antiviral status.
Share